[Seminar] Aandachtstekortstoornis met hyperactiviteit

januari 24, 2020 0 Door admin

Translating…

CBD Olie kan helpen bij ADHD. Lees hoe op MHBioShop.com

Huile de CBD peut aider avec TDAH. Visite HuileCBD.be

Summary

Attention-deficit hyperactivity disorder (ADHD), like other psychiatric disorders, represents an evolving construct that has been refined and developed over the past several decades in response to research into its clinical nature and structure. The clinical presentation and course of the disorder have been extensively characterised. Efficacious medication-based treatments are available and widely used, often alongside complementary psychosocial approaches. However, their effectiveness has been questioned because they might not address the broader clinical needs of many individuals with ADHD, especially over the longer term. Non-pharmacological approaches to treatment have proven less effective than previously thought, whereas scientific and clinical studies are starting to fundamentally challenge current conceptions of the causes of ADHD in ways that might have the potential to alter clinical approaches in the future. In view of this, we first provide an account of the diagnosis, epidemiology, and treatment of ADHD from the perspective of both the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders and the eleventh edition of the International Classification of Diseases. Second, we review the progress in our understanding of the causes and pathophysiology of ADHD on the basis of science over the past decade or so. Finally, using these discoveries, we explore some of the key challenges to both the current models and the treatment of ADHD, and the ways in which these findings can promote new perspectives.

To read this article in full you will need to make a payment

References

1.
- American Psychiatric Association
Diagnostic and statistical manual of mental disorders.

5th edn. American Psychiatric Association, Arlington, VA2013
2.
- WHO
International statistical classification of diseases and related health problems.

11th edn. World Health Organization, Geneva2018
3.
- Smoller JW
- Andreassen OA
- Edenberg HJ
- Faraone SV
- Glatt SJ
- Kendler KS
Psychiatric genetics and the structure of psychopathology.

Mol Psychiatry. 2019; 24: 409-420
4.
- Coghill D
- Sonuga-Barke EJS
Annual research review: categories versus dimensions in the classification and conceptualisation of child and adolescent mental disorders: implications of recent empirical study.

J Child Psychol Psychiatry. 2012; 53: 469-489
5.
- Gallo EF
- Posner J
Moving towards causality in attention-deficit hyperactivity disorder: overview of neural and genetic mechanisms.

Lancet Psychiatry. 2016; 3: 555-567
6.
- Pliszka SR
- Crismon ML
- Hughes CW
- et al.
The Texas Children’s Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder.

J Am Acad Child Adolesc Psychiatry. 2006; 45: 642-657
7.
- Scheffler RM
- Hinshaw SP
- Modrek S
- Levine P
The global market for ADHD medications.

J Health Affairs. 2007; 26: 450-457
8.
- Molina BSG
- Hinshaw SP
- Swanson JM
- et al.
The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study.

J Am Acad Child Adolesc Psychiatry. 2009; 48: 484-500
9.
- Chang Z
- Ghirardi L
- Quinn PD
- Asherson P
- D’Onofrio BM
- Larsson H
Risks and benefits of attention-deficit/hyperactivity disorder medication on behavioral and neuropsychiatric outcomes: a qualitative review of pharmacoepidemiology studies using linked prescription databases.

Biol Psychiatry. 2019; 86: 335-343
10.
- Adler LD
- Nierenberg AA
Review of medication adherence in children and adults with ADHD.

Postgrad Med. 2010; 122: 184-191
11.
- Bussing R
- Zima BT
- Gary FA
- Garvan CW
Barriers to detection, help-seeking, and service use for children with ADHD symptoms.

J Behav Health Serv Res. 2003; 30: 176-189
12.
- Barkley R.A.
Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder.

J Clin Psychiatry. 2002; 63: 10-15
13.
- WHO
ICD-11 for mortality and morbidity statistics (ICD-11 MMS), 2018 version.
14.
- Lahey BB
- Pelham WE
- Loney J
- Lee SS
- Willcutt E
Instability of the DSM-IV subtypes of ADHD from preschool through elementary school.

Arch Gen Psychiatry. 2005; 62: 896-902
15.
- Reed GM
- First MB
- Kogan CS
- et al.
Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders.

World Psychiatry. 2019; 18: 3-19
16.
- Moffitt TE
- Houts R
- Asherson P
- et al.
Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study.

Am J Psychiatry. 2015; 172: 967-977
17.
- Sibley MH
- Rhode LA
- Swanson JM
- et al.
Late-onset ADHD reconsidered with comprehensive repeated assessments between ages 10 and 25.

Am J Psychiatry. 2018; 175: 140-149
18.
- Krasner AJ
- Turner JB
- Feldman JF
- et al.
ADHD symptoms in a non-referred low birthweight/preterm cohort: longitudinal profiles, outcomes, and associated features.

J Atten Disord. 2018; 22: 827-838
19.
- Caye A
- Agnew-Blais J
- Arseneault L
- et al.
A risk calculator to predict adult attention-deficit/hyperactivity disorder: generation and external validation in three birth cohorts and one clinical sample.

Epidemiol Psychiatr Sci. 2019; 29: e37
20.
- Polanczyk GV
- Salum GA
- Sugaya LS
- Caye A
- Rohde LA
Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents.

J Child Psychol Psychiatry. 2015; 56: 345-365
21.
- Polanczyk G
- de Lima MS
- Horta BL
- Biederman J
- Rohde LA
The worldwide prevalence of ADHD: a systematic review and metaregression analysis.

Am J Psychiatry. 2007; 164: 942-948
22.
- Polanczyk GV
- Willcutt EG
- Salum GA
- Kieling C
- Rohde LA
ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis.

Int J Epidemiol. 2014; 43: 434-442
23.
- Collishaw S
Annual research review: secular trends in child and adolescent mental health.

J Child Psychol Psychiatry. 2015; 56: 370-393
24.
- Safer DJ
Is ADHD really increasing in youth?.

J Atten Disord. 2015; 22: 107-115
25.
- Rydell M
- Lundström S
- Gillberg C
- Lichtenstein P
- Larsson H
Has the attention deficit hyperactivity disorder phenotype become more common in children between 2004 and 2014? Trends over 10 years from a Swedish general population sample.

J Child Psychol Psychiatry. 2018; 59: 863-871
26.
- Simon V
- Czobor P
- Bálint S
- Mészáros Á
- Bitter I
Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis.

Br J Psychiatry. 2009; 194: 204-211
27.
- Faraone SV
- Biederman J
- Mick E
The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies.

Psychol Med. 2006; 36: 159-165
28.
- Asherson P
- Agnew-Blais J
Annual research review: does late-onset attention-deficit/hyperactivity disorder exist?.

J Child Psychol Psychiatry. 2019; 60: 333-352
29.
- Wright N
- Moldavsky M
- Schneider J
- et al.
Practitioner review: pathways to care for ADHD — a systematic review of barriers and facilitators.

J Child Psychol Psychiatry. 2015; 56: 598-617
30.
- Pliszka S
Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder.

J Am Acad Child Adolesc Psychiatry. 2007; 46: 894-921
31.
- Canadian ADHD Resource Alliance
Canadian ADHD practice guidelines.

4th edn. Canadian ADHD Resource Alliance, Toronto, ON2018
32.
- Palacio JD
- De la Peña-Olvera F
- Palacios-Cruz L
- Ortiz-León S
Algoritmo latinoamericano de tratamiento multimodal del trastorno por déficit de atención e hiperactividad (TDAH) a través de la vida.

Revista Colombiana de Psiquiatria. 2009; 38: 35-65
33.
- NICE
Attention deficit hyperactivity disorder: diagnosis and management.
34.
- World Federation of ADHD
The World Federation of ADHD guide.
35.
- Pliszka S
Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder.

J Am Acad Child Adolesc Psychiatry. 2007; 46: 894-921
36.
- Posner J
- Greenhill LL
Attention-deficit/hyperactivity disorder.

in: McVoy M Findling RL Clinical manual of child and adolescent psychopharmacology. 2nd edn. American Psychiatric Association, Arlington, VA2013
37.
- Cortese S
- Adamo N
- Del Giovane C
- et al.
Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.

Lancet Psychiatry. 2018; 5: 727-738
38.
- Castells X
- Ramos-Quiroga JA
- Rigau D
- et al.
Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis.

CNS Drugs. 2011; 25: 157-169
39.
- Faraone SV
- Buitelaar J
Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis.

Eur Child Adolesc Psychiatry. 2010; 19: 353-364
40.
- Schachter HM
- Pham B
- King J
- Langford S
- Moher D
How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis.

CMAJ. 2001; 165: 1475-1488
41.
- Greenhill L
- Kollins S
- Abikoff H
- et al.
Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD.

J Am Acad Child Adolesc Psychiatry. 2006; 45: 1284-1293
42.
- Greenhill LL
- Swanson JM
- Hechtman L
- et al.
Trajectories of growth associated with long-term stimulant medication in the multimodal treatment study of attention-deficit/hyperactivity disorder.

J Am Acad Child Adolesc Psychiatry. 2019; ()
43.
- Faraone SV
- Biederman J
- Morley CP
- Spencer TJ
Effect of stimulants on height and weight: a review of the literature.

J Am Acad Child Adolesc Psychiatry. 2008; 47: 994-1009
44.
- Klein RG
- Landa B
- Mattes JA
- Klein DF
Methylphenidate and growth in hyperactive children. A controlled withdrawal study.

Arch Gen Psychiatry. 1998; 45: 1127-1130
45.
- Ibrahim K
- Donyai P
Drug holidays from ADHD medication: international experience over the past four decades.

J Atten Disord. 2015; 19: 551-568
46.
- Chang Z
- Lichtenstein P
- Halldner L
- et al.
Stimulant ADHD medication and risk for substance abuse.

J Child Psychol Psychiatry. 2014; 55: 878-885
47.
- Molina BS
- Hinshaw SP
- Eugene Arnold L
- et al.
Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.

J Am Acad Child Adolesc Psychiatry. 2013; 52: 250-263
48.
- Biederman J
Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD.

J Clin Psychiatry. 2003; 64: 3-8
49.
- Rabiner DL
Stimulant prescription cautions: addressing misuse, diversion and malingering.

Curr Psychiatry Rep. 2013; 15: 375
51.
- Cooper WO
- Habel LA
- Sox CM
- et al.
ADHD drugs and serious cardiovascular events in children and young adults.

N Engl J Med. 2011; 365: 1896-1904
52.
- Habel LA
- Cooper WO
- Sox CM
- et al.
ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.

JAMA. 2011; 306: 2673-2683
53.
- Schwartz S
- Correll CU
Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression.

J Am Acad Child Adolesc Psychiatry. 2014; 53: 174-187
54.
- Cunill R
- Castells X
- Tobias A
- Capella D
Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.

Pharmacoepidemiol Drug Saf. 2013; 22: 961-969
55.
- Wilens TE
- Robertson B
- Sikirica V
- et al.
A randomized, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit/hyperactivity disorder.

J Am Acad Child Adoles Psychiatry. 2015; 54: 916-925
56.
- Sallee FR
- McGough J
- Wigal T
- Donahue J
- Lyne A
- Biederman J
Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.

J Am Acad Child Adolesc Psychiatry. 2009; 48: 155-165
57.
- Scahill L
- Chappell PB
- Kim YS
- et al.
A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder.

Am J Psychiatry. 2001; 158: 1067-1074
58.
- Taylor FB
- Russo J
Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder.

J Clin Psychopharmacol. 2001; 21: 223-228
59.
- Charach A
- Fernandez R
Enhancing ADHD medication adherence: challenges and opportunities.

Curr Psychiatry Rep. 2013; 15: 371
60.
- Greydanus DE
- Nazeer A
- Patel DR
Psychopharmacology of ADHD in pediatrics: current advances and issues.

Neuropsychiatric Dis Treat. 2009; 5: 171
61.
- Kortekaas-Rijlaarsdam AF
- Luman M
- Sonuga-Barke E
- Oosterlaan J
Does methylphenidate improve academic performance? A systematic review and meta-analysis.

Eur Child Adolesc Psychiatry. 2019; 28: 155-164
62.
- Barbaresi WJ
- Katusic SK
- Colligan RC
- Weaver AL
- Jacobsen SJ
Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study.

J Dev Behav Pediatr. 2007; 28: 274-287
63.
- Lichtenstein P
- Larsson H
Medication for attention deficit–hyperactivity disorder and criminality.

N Engl J Med. 2012; 367: 2006-2014
64.
- Chang Z
- Quinn PD
- Hur K
- et al.
Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes.

JAMA Psychiatry. 2012; 74: 597-603
65.
- Lee MJ
- Yang KC
- Shyu YC
- et al.
Attention-deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population-based study in Taiwan.

J Affect Disord. 2016; 189: 110-117
66.
- Chang Z
- Ghirardi
- Quinn PD
- Asherson P
- D’Onofrio BM
- Larsson H
Risks and benefits of attention-deficit/hyperactivity disorder medication on behavioral and neuropsychiatric outcomes: a qualitative review of pharmacoepidemiology studies using linked prescription databases.

Bio Psychiatry. 2019; 86: 335-343
67.
- Elia J
- Glessner JT
- Wang K
- et al.
Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder.

Nat Genet. 2011; 44: 78-84
68.
- Elia J
- Ungal G
- Kao C
- et al.
Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling.

Nature Commun. 2018; 9: 4
69.
- Whitehouse PJ
Paying attention to acetylcholine: the key to wisdom and quality of life?.

Progress Brain Res. 2004; 145: 311-317
70.
- Potter AS
- Newhouse PA
Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder.

Psychopharmacology (Berl). 2004; 176: 182-194
71.
- Shytle RD
- Silver AA
- Wilkinson BJ
- Sanberg PR
A pilot controlled trial of transdermal nicotine in the treatment of attention deficit hyperactivity disorder.

World J Biol Psychiatry. 2002; 3: 150-155
72.
- The MTA Cooperative Group
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal treatment study of children with ADHD.

Arch General Psychiatry. 1999; 56: 1073-1086
73.
- Rimestad ML
- Lambek R
- Zacher Christiansen H
- Hougaard E
Short-and long-term effects of parent training for preschool children with or at risk of ADHD: a systematic review and meta-analysis.

J Atten Disord. 2019; 23: 423-434
74.
- Cortese S
- Ferrin M
- Brandeis D
- et al.
Neurofeedback for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials.

J Am Acad Child Adolesc Psychiatry. 2016; 55: 444-455
75.
- Cortese S
- Ferrin M
- Brandeis D
- et al.
Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials.

J Am Acad Child Adolesc Psychiatry. 2015; 54: 164-174
76.
- Chacko A
- Feirsen N
- Bedard AC
- Marks D
- Uderman JZ
- Chimiklis A
Cogmed Working Memory Training for youth with ADHD: a closer examination of efficacy utilizing evidence-based criteria.

J Clin Child Adolesc Psychol. 2013; 42: 769-783
77.
- Klingberg T
- Fernell E
- Olesen PJ
- et al.
Computerized training of working memory in children with ADHD—a randomized, controlled trial.

J Am Acad Child Adolesc Psychiatry. 2005; 44: 177-186
78.
- Stevenson J
- Buitelaar J
- Cortese S
- et al.
Research review: the role of diet in the treatment of attention-deficit/hyperactivity disorder–an appraisal of the evidence on efficacy and recommendations on the design of future studies.

J Child Psychol Psychiatry. 2014; 55: 416-427
79.
- Krisanaprakornkit T
- Ngamjarus C
- Witoonchart C
- Piyavhatkul N
Meditation therapies for attention-deficit/hyperactivity disorder (ADHD).

Cochrane Database Syst Rev. 2010; 16CD006507
80.
- Wigal SB
- Emmerson N
- Gehricke JG
- Galassetti P
Exercise: applications to childhood ADHD.

J Atten Disord. 2013; 17: 279-290
81.
- Duric NS
- Assmus J
- Gundersen D
- Duric Golos A
- Elgen IB
Multimodal treatment in children and adolescents with attention-deficit/hyperactivity disorder: a 6-month follow-up.

Nord J Psychiatry. 2017; 71: 386-394
82.
- Faraone SV
- Perlis RH
- Doyle AE
- et al.
Molecular genetics of attention-deficit/hyperactivity disorder.

Biol Psychiatry. 2005; an> 57 : 1313-1323
83.
- Martin J
- O’Donovan MC
- Thapar A
- Langley K
- Williams N
84.
- Thapar A
Ontdekkingen over de genetica van ADHD in de 21ste eeuw: nieuwe bevindingen en hun implicaties.

Am J Psychiatry. i> 2018; 175 : 943-950
85.
- Nigg JT
- Knottnerus GM
- Martel MM
- et al.
Laag bloedgehalte niveaus geassocieerd met klinisch gediagnosticeerde aandachtstekortstoornis / hyperactiviteitsstoornis en gemedieerd door zwakke cognitieve controle.

Biol Psychiatry. 2008; 63 : 325-331
86.
- Nigg JT
- Breslau N
Prenatale blootstelling aan roken, laag geboortegewicht en verstorende gedragsstoornissen.

J Am Acad Child Adolesec Psychiatry. 2007; 46 : 362-369
87.
- Klasse QA
- Rickert M
- Larsson H
- Lichtenstein P
- D’Onofrio BM
Foetale groei en psychiatrische en sociaaleconomische problemen: vergelijking van populatiegebaseerde broers en zussen.

Br J Psychiatry. 2014; 205 : 355-361
88.
- Knopik VS
- Sparrow EP
- Madden PA
- et al.
Bijdragen van ouders alcoholisme, prenatale blootstelling aan stoffen en genetische overdracht op ADHD-risico bij kinderen: een tweelingstudie bij vrouwen.

Psychol Med. 2005; 35 : 625-635
89.
- McCann D
- Barrett A
- Cooper A
- et al.
Voedingssupplementen en hyperactief gedrag bij 3-jarige en 8/9-jarige kinderen in de gemeenschap: een gerandomiseerde, dubbelblinde, placebo-gecontroleerde studie.

Lancet. 2007; 370 : 1560-1567
90.
- Nigg JT
- Elmore AL
- Natarajan N
- Friderici KH
- Nikolas MA
91.
- Harold GT
- Leve LD
- Barrett D
- et al.
Biologisch en grootbrengen moederinvloeden op ADHD-symptomen bij kinderen: het herzien van de ontwikkelingsinterface tussen natuur en opvoeding.

J Kinderpsychologie Psychiatrie. 2013; 54 : 1038-1046
92.
- Kennedy M
- Kreppner J
- Knights N
- et al.
Vroege ernstige institutionele deprivatie wordt geassocieerd met een persistente variant van aandachtstekortstoornis / hyperactiviteit bij volwassenen: klinische presentatie, ontwikkelingsstoornissen en levensomstandigheden in de Engelse en Roemeense Adoptees-studie.

J Child Psychol Psychiatry. i > 2016; 57 : 1113-1125
93.
- Lugo-Candelas C
- Monnik C
- Duarte CS
- Lee S
- Posner J
Gedeelde genetische factoren, foetale programmering en de overdracht van depressie.

Lancet Psychiatry. 2018; 5 : 771-773
94.
- Nigg J
- Nikolas M
- Burt SA
Gemeten gen-per-omgeving interactie in relatie tot aandachtstekort / hyperactiviteitsstoornis.

J Am Acad Child Adolesc Psychiatry. 2010; 49 : 863-873
95.
- Walton E
- Pingault JB
- Cecil CA
- et al.
Epigenetische profilering van ADHD-symptoomtrajecten: een prospectieve, methyloombrede studie.

Mol Psychiatry. 2017; 22 : 250-256
96.
- Barker ED
- Walton E
- Cecil CAM
Jaarlijkse onderzoeksevaluatie: DNA-methylatie als bemiddelaar in de associatie tussen risicoblootstelling en kinder- en jeugdpsychopathologie.

J Kinderpsycholpsychiatrie. 2018; 59 : 303-322
97.
- Kuntsi J
- Eley TC
- Taylor A
- et al.
Gelijktijdig optreden van ADHD en laag IQ heeft genetische oorsprong.

Am J Med Genet B Neuropsychiatr Genet. 2004; 124B : 41-47
98.
- Posner J
- Rauh V
- Gruber A
- Gat I
- Wang Z
- Peterson BS
Dissocieerbare aandachts- en affectieve circuits bij medicatie-naïeve kinderen met aandachtstekort- / hyperactiviteitsstoornis.

Psychiatry Res. 2013; 213 : 24-30
99.
- Brown TE
ADD / ADHD en verminderde uitvoerende functie in de klinische praktijk.

Curr Atten Disord Rep. 2009; 1 : 37-41
100.
- Nigg JT
- Willcutt EG
- Doyle AE
- Sonuga-Barke EJ
Causale heterogeniteit bij aandachtstekort / hyperactiviteitsstoornis: hebben we neuropsychologisch gehandicapte subtypen nodig?

Biol Psychiatry. 2005; 57 : 1224-1230
101.
- Castellanos FX
- Sonuga-Barke EJ
- Milham MP
- Tannock R
Kenmerkend voor cognitie in ADHD: verder dan uitvoerende disfunctie.

Trends Cogn Sci. 2006; 10 : 117-123
102.
- Velligan DI
- Bow-Thomas C
Uitvoerende functie bij schizofrenie.

Semin Clin Neuropsychiatry. 1999; 4 : 24-33
103.
- Mur M
- Portella MJ
- Martínez-Arán A
- Pifarré J
- Vieta E
Persistent neuropsychologisch tekort bij euthymische bipolaire patiënten: executieve functie als kerntekort.

J Clin Psychiatry. 2007; 68 : 1078-1086
104.
- O’Hearn K
- Asato M
- Ordaz S
- Luna B
Neurologische ontwikkeling en uitvoerende functie bij autisme.

Dev Psychopathol. 2008; 20 : 1103-1132
105.
- Kofler MJ
- Raiker JS
- Sarver DE
- Wells EL
- Soto EF
106.
- McInerney RJ
- Kerns KA
Tijdreproductie bij kinderen met ADHD: motivatie is belangrijk.

Kind Neuropsychol . 2003; 9 : 91-108
107.
- Sonuga-Barke E
- Bitsakou P
- Thompson M
Voorbij het dual pathway-model: bewijs voor de dissociatie van timing, remmende en vertragingsgerelateerde stoornissen bij aandachtstekortstoornis / hyperactiviteitsstoornis.

J Am Acad Child Adolesc Psychiatry. 2010; 49 : 345-355
108.
- Sergeant J
Het cognitief-energetische model: een empirische benadering van aandachtstekortstoornis met hyperactiviteit.

Neurosci Biobehav Rev. 2000; 24 : 7-12
109.
- Sonuga-Barke EJ
Psychologische heterogeniteit in AD / HD – een tweevoudig pathway-model van gedrag en cognitie.

Gedrag Brain Res . 2002; 130 : 29-36
110.
- James SN
- Cheung CHM
- Rijsdijk F
- Asherson P
- Kuntsi J
111.
- Straub M
- Ulke C
- Paucke M
- et al.
Regulatie van de hersenen bij volwassenen met aandachtstekort / hyperactiviteitsstoornis (ADHD).

Psychiatry Research. 2018; 261 : 102-108
112.
- Metin B
- Roeyers H
- Wiersema JR
- van der Meere J
- Sonuga-Barke E li>
Een meta-analytische studie van event rate effecten op go / no-go prestaties bij aandachtstekort / hyperactiviteitstoornis.

Biol Psychiatry. 2012; 72 : 990-996
113.
- Castellanos FX
- Giedd JN
- Marsh WL
- et al.
Kwantitatieve hersens magnetisch resonantiebeeldvorming bij aandachtstekortstoornis met hyperactiviteit.

Arch Gen Psychiatry. 1996; 53 : 607-616
114.
- Filipek PA
- Semrud-Clikeman M
- Steingard RJ
- Renshaw PF
- Kennedy DN
- Biederman J
Volumetrische MRI-analyse waarbij personen met een aandachtstekortstoornis met hyperactiviteit vergeleken worden met normale controles.

Neurologie. 1997; 48 : 589-601
115.
- Shaw P
- Eckstrand K
- Sharp W
- et al.
Aandachtstekort / hyperactiviteitsstoornis wordt gekenmerkt door een vertraging in corticale rijping.

Proc Natl Acad Sci USA. 2007; 104 : 19649-19654
116.
- Posner J
- Park C
- Wang Z
Verbind de punten: een overzicht van rustende connectiviteit MRI-studies in aandacht -deficit / hyperactiviteitsstoornis.

Neuropsychol Rev. 2014; 24 : 3-15
117.
- Eerlijke DA
- Posner J
- Nagel BJ
- et al.
Atypisch standaardnetwerk connectiviteit bij jongeren met aandachtstekort / hyperactiviteitsstoornis.

Biol Psychiatry. 2010; 68 : 1084-1091
118.
- Sonuga-Barke EJ
- Castellanos FX
Spontane aandachtsschommelingen in verminderde toestanden en pathologische aandoeningen: een neurobiologische hypothese.

Neurosci Biobehav Rev. 2007; 31 : 977-986
119.
- Cha J
- Fekete T
- Siciliano F
- et al.
Neurale correlaten van agressie bij medicatie-naïeve kinderen met ADHD: multivariate analyse van morfometrie en tractografie.

Neuropsychopharmacology. 2015; 40 : 1717-1725
120.
- Hoogman M
- Bralten J
- Hibar DP
- et al.
Subcorticaal hersenvolume verschillen in deelnemers met aandachtstekortstoornis met hyperactiviteit bij kinderen en volwassenen: een cross-sectionele mega-analyse.

Lancet Psychiatry. 2017; 4 : 310-319
121.
- Plichta MM
- Scheres A
Ventral-striatale responsiviteit tijdens anticipatie op beloning bij ADHD en de relatie met eigenschapimpulsiviteit in de gezonde populatie: een meta -analytische beoordeling van de fMRI-literatuur.

Neurosci Biobehav Rev. 2014; 38 : 125-134
122.
- Konrad A
- Dielentheis TF
- El Masri D
- et al.
Verstoorde structurele connectiviteit is gerelateerd aan onoplettendheid en impulsiviteit bij volwassenen met aandachtstekortstoornis met hyperactiviteit.

Eur J Neurosci. 2010; 31 : 912-919
123.
- Wang Y
- Bernanke J
- Peterson BS
- et al.
De associatie tussen antidepressiva en hersenconnectiviteit in twee dubbelblinde, placebo-gecontroleerde klinische onderzoeken: een onderzoek naar behandelingsmechanismen.

Lancet Psychiatry. 2019; 6 : 667-674
124.
- Swanson JM
- Wigal T
- Lakes K
DSM-V en de toekomstige diagnose van aandachtstekort / hyperactiviteit wanorde.

Curr Psychiatry Rep. 2009; 11 : 399-406
125.
- Posner J
De rol van precisiegeneeskunde in de kinderpsychiatrie: wat kunnen we verwachten en wanneer?

J Am Acad Child Adolesc Psychiatry. 2018; 57 : 813-817
126.
- Campbell SB
- Halperin JM
- Sonuga-Barke EJS
Een ontwikkelingsperspectief op aandachtstekort / hyperactiviteitsstoornis ( ADHD).

in: Lewis M Rudolph KD Handboek voor ontwikkelingspsychopathologie. Springer span>, Boston, MA, VS 2014 : 427-448
127.
- Franke B
- Michelini G
- Asherson P
- et al.
Leef snel, sterf jong? Een overzicht van de ontwikkelingstrajecten van ADHD gedurende de levensduur.

Eur Neuropsychopharmacol. 2018; 28 : 1059-1088
128.
- Halperin JM
- Bédard AC
- Curchack-Lichtin JT
Preventieve interventies voor ADHD: een neurologisch perspectief. p> Neurotherapeutica. 2012; 9 : 531-541
129.
- Smith E
- Meyer BJ
- Koerting J
- et al.
Voorschoolse hyperactiviteit specifiek verhoogt de geestelijke gezondheidsrisico’s op lange termijn sterker bij mannen dan bij vrouwen: een prospectief longitudinaal onderzoek tot jongvolwassenheid.

Eur Child Adolesc Psychiatry. 2017; 26 : 123-136
130.
- Goodwin A
- Salomone S
- Bolton P
- et al.
Aandachtstraining voor zuigelingen met familiaal risico op ADHD (INTERSTAARS): studieprotocol voor een gerandomiseerde gecontroleerde trial.

Trials. 2016; 17 : 608
131.
- Daley D
- Van Der Oord S
- Ferrin M
- et al.
Beoordeling door de beoefenaar: huidige beste praktijk in het gebruik van oudertraining en andere gedragsinterventies bij de behandeling van kinderen en adolescenten met een aandachtstekortstoornis met hyperactiviteit.

J Child Psychol Psychiatry. 2018; 59 : 932-947
132.
- Casey BJ
- Oliveri ME
- Insel T
Een neurologisch perspectief op het raamwerk van onderzoeksdomeincriteria (RDoC).

Biol Psychiatry. 2014; 76 : 350-353
133.
- Johnson MH
- Gliga T
- Jones E
- Charman T
Jaarlijks onderzoeksoverzicht: babyontwikkeling, autisme en ADHD – vroege wegen naar opkomende aandoeningen.

J Child Psychol Psychiatry. 2015; 56 : 228-247
134.
- Nomura Y
- Marks DJ
- Grossman B
- et al.
Blootstelling aan zwangerschap diabetes mellitus en lage sociaal-economische status: effecten op neurocognitieve ontwikkeling en risico op aandachtstekort / hyperactiviteitsstoornis bij nakomelingen.

Arch Pediatr Adolesc Med. 2012; 166 : 337-343
135.
- Peleg-Raibstein D
- Sarker G
- Litwan K
- et al.
Verbeterd gevoeligheid voor misbruik van drugs en smakelijk voedsel na overnames van de moeder.

Transl Psychiatry. 2016; 6 : e911
136.
- Edlow AG
Maternale obesitas en neurologische en psychiatrische stoornissen bij nakomelingen.

Prenat Diagn. 2017; 37 : 95-110
137.
- Buse J
- Schoenefeld K
- Münchau A
- Roessner V
Neuromodulatie bij Tourette syndroom : dopamine en verder.

Neurosci Biobehav Rev. 2013; 37 : 1069-1084

Uncited Reference

50.
- Gould MS
- Walsh BT
- Munfakh JL
- et al.
Plotselinge dood en gebruik van stimulerende medicijnen bij jongeren.

Am J Psychiatry. 2009; 166 : 992-1001